Skip to content
MedsAcross

Molecule

Cefoxitin

Also known as cefoxitin sodium
Available on requestAntibiotics
Presentations
6
Brands
0
Manufacturers
0
Available from stock
0

Cefoxitin is a cephalosporin antibacterial indicated for the treatment of infections caused by susceptible isolates of the designated bacteria, among other approved uses. It is available as powder for injection and injection for intravenous use. MedsAcross supplies Cefoxitin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Cephalosporin Antibacterial
ATC classification
J01DC01 Cefoxitin · Cephalosporin antibiotic
US FDA first approval
18 October 1978
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Intravenous
Dosage forms
Powder for injection, Injection
Identifiers
UNII 6OEV9DX57YRxCUI 2189CAS 35607-66-0DrugBank DB01331Q2353907

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

Cefoxitin for Injection and Dextrose Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible isolates of the designated bacteria: Lower respiratory tract infections, Urinary tract infections, Intra-abdominal infections, Gynecological infections, Septicemia, Bone and joint infections, Skin and skin structure infections, Prophylaxis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefoxitin for Injection and Dextrose Injection and other antibacterial drugs, Cefoxitin for Injection and Dextrose Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Source: US FDA prescribing information

Dosing overview

For intravenous use only. Use this formulation of cefoxitin only in patients who require the entire 1 or 2 gram dose and not any fraction thereof. See full prescribing information for dose adjustment in patients with impaired renal function. Recommended dosing schedule in patients with normal renal function.

Source: US FDA prescribing information

Contraindications

Hypersensitivity to cefoxitin or other beta-lactam antibacterial drugs. Hypersensitivity to corn products. Hypersensitivity to Cefoxitin or other Beta-lactam Antibacterial Drugs Cefoxitin for Injection and Dextrose Injection is contraindicated in patients who have shown hypersensitivity to cefoxitin or to other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins). Hypersensitivity to Corn Products Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

Source: US FDA prescribing information

Warnings and precautions

Hypersensitivity reactions including anaphylaxis and serious skin reactions. If an allergic reaction occurs, discontinue the drug. Use in patients with renal impairment: Dosage adjustment required for patients with impaired renal function. Clostridium difficile -associated diarrhea: May range from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.

Source: US FDA prescribing information

Side effects

The following clinically significant adverse reactions are discussed in greater detail in other sections of labeling: • Hypersensitivity Reactions to Cefoxitin or other Beta-lactam Antibacterial Drugs • Use in Patients with Renal Impairment • Clostridium difficile -associated Diarrhea • Risk of Development of Drug-resistant Bacteria • Drug/Laboratory Test Interactions • Patients with a History of Gastrointestinal Disease • Patients with Overt or Known Subclinical Diabetes Mellitus or Carbohydrate Intolerance The most common adverse reactions have been local reactions following intravenous injection. Local Reactions Thrombophlebitis has occurred with intravenous administration.

Source: US FDA prescribing information

Interactions

Aminoglycosides: Increased potential of nephrotoxicity. Aminoglycosides Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibacterials.

Source: US FDA prescribing information

Storage

Storage Store the unactivated unit at 20-25°C (68-77°F). Excursions permitted to 15-30°C (59-86°F). Do not freeze. As with other cephalosporins, reconstituted Cefoxitin for Injection and Dextrose Injection tends to darken depending on storage conditions, within the stated recommendations.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

6 presentations of Cefoxitin, sorted by availability.

MedicineManufacturerRegisterAvailability
Cefoxitin 1 g powder for injectionIntravenousGeneric name—US FDAAvailable on request
Cefoxitin 2 g powder for injectionIntravenousGeneric name—US FDAAvailable on request
Cefoxitin 10 g powder for injectionIntravenousGeneric name—US FDAAvailable on request
Cefoxitin 1 g/50 mL injectionIntravenousGeneric name—US FDAAvailable on request
Cefoxitin 100 g powder for injectionIntravenousGeneric name—US FDAAvailable on request
Cefoxitin 2 g/50 mL injectionIntravenousGeneric name—US FDAAvailable on request

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 18 October 1978Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Conditions

Conditions linked to Cefoxitin in public data. This is not a list of approved uses, see the clinical information.

Abscess Bacteroides infectious disease Escherichia coli infectious disease Female reproductive system disease Gram-negative bacterial infection Infectious bone disease Peritonitis Postoperative complications Sepsis Staphylococcal infection Upper respiratory tract infection Urinary tract infection

Questions and answers

Is Cefoxitin available for export from India?

Yes, on request. MedsAcross lists 6 presentations of Cefoxitin and sources them for licensed hospitals, importers and physicians against valid import documents.

Is Cefoxitin approved by the US FDA?

Yes. The US FDA first approved Cefoxitin on 18 October 1978, according to Drugs@FDA.

Does Cefoxitin need cold chain shipping?

No listed presentation of Cefoxitin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Cefoxitin in?

Cefoxitin is classified under ATC code J01DC01 (Cefoxitin).

References

  1. Cefoxitin and Dextrose prescribing information (B. Braun Medical). U.S. National Library of Medicine, DailyMed. Retrieved 29 July 2019

Request Cefoxitin for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.

Request a quoteRead the import guides